Actively Recruiting
Study of Muscle Loss in Advanced Lung Cancer and How Exercise May Help Investigating Molecular Causes and Effects on Patients and Caregivers
Led by University of Copenhagen · Updated on 2022-05-16
144
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
U
University of Copenhagen
Lead Sponsor
R
Rigshospitalet, Denmark
Collaborating Sponsor
AI-Summary
What this Trial Is About
Muscle mass loss is a common and serious problem in people with cancer, especially in those with metastatic lung cancer. This condition, called cancer cachexia, involves involuntary weight loss and affects up to 80% of such patients. Researchers are investigating the molecular causes of muscle and fat loss, hormone sensitivity, and the role of exercise in potentially restoring muscle function and improving quality of life for both patients and their caregivers. The study aims to fill important gaps in knowledge about cancer cachexia and its impact on health and survival. The study includes three parts first, examining hormone sensitivity and physical performance in patients with lung cancer undergoing their first type of cancer treatment second, analyzing changes in muscle, fat, and blood samples to understand disease progression and third, testing an exercise program involving supervised single-leg kicking training for 8 weeks to see if it can improve muscle signaling and function. Control subjects matched for age, weight, gender, and activity level will also participate in the exercise intervention. Participants will undergo assessments including muscle mass and disease outcome measurements after 12 weeks, insulin sensitivity testing at 8 weeks, and surveys on quality of life. Muscle and tissue samples will be collected to study molecular changes. The study will monitor physical function, hormone sensitivity, and patient-reported outcomes to understand the effects of cancer and exercise over time. Total participation duration varies with study parts but includes multiple visits for testing and training sessions.
CONDITIONS
Brief Title
Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 18 years or older
- Diagnosed with histologically and radiologically confirmed non-small cell lung cancer (NSCLC) stage IIIb or IV
- Not eligible for concurrent chemo/radiation therapy as primary treatment (WP1 and WP2)
- Referred for first-line palliative anticancer therapy (platin-based, immunotherapy, combined therapy, or TKI) for WP1 and WP2
- Referred for palliative anticancer therapy for recurrent cancer (WP2X)
- Have a staging or baseline CT or PET/CT scan within 4 weeks before starting treatment or planned within the first week of treatment
- ECOG Performance Status between 0 and 2
- Have signed the informed consent form
You will not qualify if you...
- Any other active malignancy requiring treatment (previous cancer treatment completed is allowed)
- Receiving local palliative radiotherapy as primary treatment
- ECOG Performance Status greater than 2
- Physical disabilities that prevent physical testing
- Inability to understand Danish language
- Inability to comprehend scoring systems or patient-reported outcome measures
Research Team
J
Jonas Sørensen, MD.
L
Lykke Sylow, Ass.proff
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here